Calif. Supreme Court Backs Gilead 6-1 in Innovate Case
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- California Supreme Court sided 6-1 with Gilead Sciences, overturning a state appeals court ruling from two years ago that had allowed the company to be held liable for slow-walking development of a safer HIV medicine.
- More than 24,000 patients sued in federal and state court claiming they unnecessarily suffered kidney injury and bone loss from Gilead's older HIV drug while the safer alternative was delayed.
- Gilead stood accused by plaintiffs of cynically managing its product pipeline — prioritizing the existing drug over a replacement that could have spared patients harm.
- Pharmaceutical industry groups had raised alarms after the 2022 appellate ruling, warning that exposing drugmakers to legal liability for R&D pacing decisions could chill development.
- The case tested whether drugmakers owe a legal "duty" to innovate faster — accelerating development of safer successors to drugs they already sell.
Why it matters: By overturning the appellate ruling 6-1, California's high court shields drugmakers from 'duty to innovate' liability; the 24,000-plus patient lawsuits lose their state-court foothold, and pharma R&D pacing decisions remain driven by science and commerce rather than litigation fear.
